Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
- 201 Downloads
Oral abiraterone acetate (Zytiga®), a selective cytochrome P450 17A1 enzyme inhibitor, is used in combination with prednisone or prednisolone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. In a clinical trial in patients with CRPC, abiraterone acetate plus prednisone significantly prolonged overall survival, the time to prostate-specific antigen progression and progression-free survival compared with placebo plus prednisone.
Acknowledgements and Disclosures
This article was adapted from Drugs 2011; 71 (15): 2067–77, and was reviewed by: E. Obarcanin, Sarajevo, Bosnia and Herzegovina; N. Reynolds, Auckland City Hospital, Auckland, New Zealand; S. Saluja, Consultant in Internal Medicine, Saran Ashram, Agra, India.
The preparation of this article was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.
- 3.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): prostate cancer (version 4.2011). Fort Washington (PA): National Comprehensive Cancer Network, 2011Google Scholar
- 7.Zytiga 250mg tablets: summary of product characteristics. London: European Medicines Agency, 2011 Dec 14Google Scholar
- 8.Zytiga™ (abiraterone acetate) oral tablets: US prescribing information. Horsham (PA): Centocor Ortho Biotech Inc., 2011 AprGoogle Scholar
- 10.Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract no. LBA4517]. J Clin Oncol 2011 Jun 20; 29(18 Suppl.)Google Scholar
- 11.Fizazi K, Scher HI, Molina A, et al. Final overall survival (OS) analysis of COU-AA-301, a phase 3 study of abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) pretreated with docetaxel [abstract no. 7000]. 2011 European Multi-disciplinary Cancer Congress; 2011 Sep 23–27; StockholmGoogle Scholar
- 12.Bianchini D. Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC) [abstract no. 4672]. J Clin Oncol 2010 May 20; 28(15 Suppl.)Google Scholar
- 13.Cougar Biotechnology Inc. Abiraterone acetate in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer [ClinicalTrials.gov identifier NCT00887198]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Sep 16]